Condition: Tricuspid Regurgitation · Sponsor: Hangzhou Valgen Medtech Co., Ltd
The primary objective of this trial is to demonstrate the safety and effectiveness of the DragonFly-T system in improving clinical outcomes in symptomatic patients with severe tricuspid regurgitation (TR), who are at intermediate or greater estimated risk for mortality or morbidity with tricuspid valve surgery. This randomized controlled trial will compare the investigational device (DragonFly-T system) to Control (Medical Therapy).
This description comes directly from the study's public registry record.
Bo Liu · +8613001980902 · bo.liu@valgenmed.com
Shuangjie Li · +8617756106609 · shuangjie.li@valgenmed.com
Always discuss trial participation with your own doctor first.
| West China Hospital of Sichuan University | Chengdu, Sichuan, China | Recruiting |
| The Second Affiliated Hospital Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05556460